Swiss Acino, Saudi’s Alpha partner to attain Saudi National Vision 2030

By Salma C, Intern Reporter
  • Follow author on
Alpha Acino
Dr. Andrew Bird, GM and Head of Region, Middle East, Turkey and Africa, Acino, Mr. Yaser Y. Naghi, CEO Alpha Pharma and other top officials at agreement signing ceremony

Acino, a Swiss-based pharmaceutical company, has partnered with Saudi Arabia’s Alpha Pharma to meet the aspirations of the Saudi health sector transformation program launched as part of National Vision 2030.

The partnership agreement was signed by Dr. Andrew Bird, General Manager and Head of Region, Middle East, Turkey, and Africa, Acino, and Mr. Yaser Y. Naghi, CEO of Cigalah Health Care company and its subsidiary Alpha Pharma.

HE Abdullah Al Masoud, Saudi Commercial Attaché to Switzerland, Mr. Steffen Saltofte, CEO of Acino, Mr. Fahad Al Otaibi, Acino’s Country Manager for Saudi Arabia and Dr. Murad Al Saggaf, General Manager, Alpha Pharma were also present at the occasion.

Commenting on the partnership, H.E. Abdullah Al Masoud remarked that, “Partnerships like these are a step in the right direction towards achieving the Saudi Vision 2030 and the Health Sector Transformation Programme. We commend the efforts of Acino in expanding its presence in the Kingdom, and striking collaborations with organizations such as Alpha Pharma to increase access to treatments for patients who need them most.”

Saudi Arabia’s health sector transformation program, which is considered a key component of the National Transformation Program, focuses on improving the quality and effectiveness of health care and optimizing treatment outcomes. In collaboration with Alpha, Acino will enhance its commitment to offering better access to high-quality essential medicines for patients and health care providers.

Acino and Alpha collaboration will cover several therapeutic areas, including Acino Drugs for gastro/gastric, duodenal ulcers, gastroesophageal reflux disease (GERD), and pain management. These products are expected to be available across the Kingdom by 2023.

Meanwhile, Mr. Fahad Al Otaibi, Country Manager for Saudi Arabia, Acino, remarked that “Acino is committed to advancing the development of healthcare across Saudi Arabia by accelerating access to high-quality medicines that patients and the government can trust and value.

“As part of our expansion in the Kingdom, our partnership with Alpha will allow us to further enhance patient services and promote higher standards. We shall work diligently and tirelessly towards better outcomes in care that lay the foundation for a more prosperous society,” Mr. Al Otaibi added.

For his part, Dr. Murad Al Saggaf, GM, Alpha Pharma commented that “This agreement between Alpha Pharma and Acino is a key step in the furtherance of the goals that underpin the Health Sector Transformation Program, the National Transformation Program, and Vision 2030. Our collaboration will feed directly into the country’s ongoing enhancement of key services. By enhancing access to affordable high-quality medicines, we strengthen a vital part of the healthcare industry and align with national initiatives aimed at building a healthier, happier society.”

Related: IMC Jeddah takes a pioneering approach in healthcare with Digitalization